Two landmark clinical trials, namely CREATE-X (UMIN000000843) for residual triple negative [7] and KATHERINE (NCT01772472) for residual Her2+ [8] breast cancers, both demonstrated improved invasive disease-free survival (DFS) with postoperative capecitabine and ado-trastuzumab emtansine (TDM1) respectively. Here, ERBB2 is linked to breast carcinoma.